Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 07, 2026
AXTX: Tradr 2X Long AXTI Daily ETF Gains +15% in 30 Days but Declines -77% Over the Quarter

AXTX: Tradr 2X Long AXTI Daily ETF Gains +15% in 30 Days but Declines -77% Over the Quarter

Key Takeaways

  • AXTX gained approximately 15% over the past 30 days, recovering from extreme lows as underlying stock AXTI rallied on transformative corporate developments.
  • Over the last quarter, AXTX has declined roughly 77%, illustrating the severe compounding and volatility decay effects inherent to daily-reset leveraged exchange-traded funds (ETFs).
  • The primary catalyst was AXT, Inc.'s record Q2 2026 earnings, which featured revenue of $47.6 million (+164% year-over-year) and a definitive return to profitability, alongside multiple long-term indium phosphide supply agreements.
  • As a 2x leveraged single-stock ETF with a 1.49% expense ratio, AXTX is designed exclusively for short-term tactical trading and magnifies both daily gains and losses in the underlying security.
  • AI-driven demand for indium phosphide substrates used in data center optical connectivity remains the dominant investment theme, with AXTI's backlog exceeding $100 million.

Understanding the Tradr 2X Long AXTI Daily ETF (AXTX) and Its Exposure

The Tradr 2X Long AXTI Daily ETF seeks daily investment results, before fees and expenses, that correspond to 200% of the daily performance of the common shares of AXT, Inc. (AXTI). Launched on April 24, 2026 and managed by AXS Investments LLC under the Tradr ETFs brand, the fund is actively managed and maintains at least 80% exposure to financial instruments — primarily swaps and derivatives — that provide two times leveraged exposure to AXTI. It carries a net expense ratio of 1.49% and is structured as a non-diversified fund. I also checked comparable leveraged products using Tickeron’s AI Screener to see how AXTX fits within the broader industry landscape.

AXT, Inc. is a materials science company that designs, develops, and manufactures high-performance compound and single-element semiconductor substrate wafers, including indium phosphide (InP), gallium arsenide (GaAs), and germanium (Ge). The company supplies substrates used in 5G infrastructure, data center silicon photonics, passive optical networks, lasers, sensors, and satellite solar cells. Its manufacturing operations are primarily located in China, with headquarters in Fremont, California. This concentrated single-stock exposure — amplified by 2x daily leverage — makes AXTX one of the most volatile ETFs available, entirely dependent on AXTI's share price trajectory.

AXTX Price Performance: 30-Day Rebound Versus Quarterly Drawdown

Over the last 30 days, AXTX rose from a closing price of $9.60 on July 8, 2026, to $11.01 on August 6, 2026 — a gain of approximately 15%. This advance was neither linear nor orderly. The ETF continued to slide through mid-July, bottoming at $3.01 on July 29, before a powerful multi-session reversal propelled it back into the double digits. The rally was compressed into a handful of trading sessions following AXTI's late-July catalyst cluster.

The quarterly picture tells a starkly different story. From a closing price of $48.42 on May 7, 2026, AXTX has declined roughly 77% to its current level. The fund reached an all-time high of $73.02 on May 22 before a punishing multi-month drawdown erased the overwhelming majority of its value. This divergence between the 30-day bounce and the quarterly collapse highlights the path-dependent nature of daily-reset leveraged products: even when the underlying stock stages a sharp recovery, the mathematical compounding of daily returns during periods of high volatility can permanently impair fund NAV (Net Asset Value) for holders who remain invested beyond a single trading session.

Key Drivers Behind AXTX’s 30-Day Move

The last 30 days were defined by a dramatic pivot in AXTI's fundamental narrative. The single most consequential event was AXT, Inc.'s Q2 2026 earnings release on July 30, which dramatically exceeded consensus expectations. The company reported record quarterly revenue of $47.6 million, up 164% year-over-year, and non-GAAP earnings per share (EPS) of $0.19 — surpassing the $0.07 consensus estimate by over 170%. Non-GAAP gross margin expanded to 45.0%, up from 29.9% in the prior quarter. Indium phosphide revenue alone reached a record $30.7 million, cementing InP as the company's primary growth engine.

Just one day earlier, on July 29, AXT announced a definitive long-term supply and capacity reservation agreement with LITE (Lumentum Operations), under which Lumentum committed to $87 million in deposits applied as shipment credits through 2031. This followed earlier agreements with COHR (Coherent) and Casela, together representing over $130 million in customer prepayments. These agreements validated the thesis that AI data center demand for indium phosphide substrates — the critical material in high-speed optical transceivers — is structural rather than cyclical. Needham & Company upgraded AXTI to Buy with a $90 price target on July 31, further reinforcing positive sentiment. AXTI shares, which had fallen as low as $36.97 on July 29, surged to $75.17 by August 6, and AXTX — amplified by 2x leverage — followed sharply higher.

Factors Behind the Quarterly Performance Decline

The broader three-month trend was dominated by a severe and prolonged sell-off that wiped out more than three-quarters of the ETF's value. AXTI entered May 2026 trading above $100 per share, propelled by extraordinary year-to-date gains exceeding 650% as investors priced in the AI-driven indium phosphide growth story. However, multiple headwinds converged to trigger a brutal reversal. A short report from J Capital Research alleged that Chinese regulators had blocked the IPO of AXTI's Tongmei subsidiary, accusing the company of tax evasion and questioning the authenticity of its AI-linked demand narrative. Insider selling intensified, with over $43 million in AXTI shares sold by company executives and directors during the quarter.

Valuation concerns also weighed heavily. At its May peak near $143, AXTI traded at a trailing price-to-earnings (P/E) ratio exceeding 400x, with independent fair-value models suggesting the stock was thousands of percent overvalued relative to historical fundamentals. A proposed increase in authorized shares from 70 million to 120 million — intended to fund indium phosphide capacity expansion — sparked dilution fears. The combination of these factors drove AXTI down more than 70% from peak to trough, and AXTX, with its 2x daily multiplier subject to volatility decay, suffered a far deeper drawdown of approximately 95% from its May high.

AXTX ETF Outlook: Factors to Monitor

The trajectory of AXTX will remain inextricably linked to AXTI's share price and the durability of the AI-driven indium phosphide demand narrative. Several factors merit close attention in the months ahead. First, AXTI's Q3 2026 execution against its guidance of approximately $66 million in revenue and non-GAAP EPS of $0.30–$0.32 will test whether the Q2 inflection was a one-time event or the beginning of a sustained earnings cycle. Second, export permit dynamics remain a persistent risk: AXTI's Chinese manufacturing base means that U.S. export controls and regulatory friction could disrupt revenue recognition and capacity expansion timelines. Third, the company's plan to triple indium phosphide capacity by end-2027 — targeting approximately $130 million in quarterly capacity — will require flawless operational execution and sustained customer demand.

From a structural perspective, investors should recognize that AXTX is not designed for multi-day holding periods. The mathematical effects of daily reset and compounding mean that even if AXTI shares appreciate over time, AXTX may significantly underperform or lose value during periods of elevated volatility. The ETF's 1.49% expense ratio further compounds the cost of holding the fund beyond very short time horizons. For those monitoring the broader semiconductor substrate industry, the supply-demand imbalance in indium phosphide — where global demand is estimated at roughly 260–300 million wafer equivalents against effective capacity of approximately 75 million — suggests that pricing power and backlog growth could persist, though geopolitical disruption, competitive capacity additions, and shifts in AI capital expenditure trends represent material risks to the thesis.

Using Tickeron’s AI Screener in My Analysis

In reviewing leveraged ETFs like AXTX, I frequently rely on Tickeron’s AI Screener to scan for comparable instruments and emerging patterns across the sector. This AI-powered platform lets me apply technical indicators, volatility filters, and performance metrics to quickly surface relevant opportunities that align with a short-term trading approach. It has proven especially useful when evaluating high-volatility products tied to single-stock themes. Explore the AI Screener for your own data-driven screening needs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXTX

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


AXTX sees its Stochastic Oscillator ascending out of oversold territory

On September 17, 2026, the Stochastic Oscillator for AXTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 4 instances where the indicator left the oversold zone. In 4 of the 4 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on AXTX as a result. In 2 of 3 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

The Moving Average Convergence Divergence (MACD) for AXTX just turned positive on September 09, 2026. Looking at past instances where AXTX's MACD turned positive, the stock continued to rise in 1 of 1 cases over the following month. The odds of a continued upward trend are 90%.

Following a +18.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXTX advanced for three days, in 18 of 21 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Aroon Indicator for AXTX entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of AXT, Inc. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of AXTI. It is non-diversified.
View a ticker or compare two or three
AXTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
VIA fell over 11% today, extending a slide that began last week; the stock has been under pressure since trading around the high‑teens and low‑$20s, well below its $46 IPO price.
LAES fell more than 19% today as the market digested a $125 million registered direct offering of 30.4 million new shares (or pre‑funded warrants) plus warrants for up to 60.8 million additional shares, all priced at $4.11 per unit.
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.